Answers are grounded in this paper and cite their sources.
The recent discoveries of potent HSP90 and MAP kinase inhibitors amongst the resorcylic acid lactones (RALs) have revived interest in this family of natural products. Both HSP90 and MAP kinase inhibition hold tremendous therapeutic potential, particularly in the treatment of cancer. Our synthetic efforts towards the RALs and, in particular, selective inhibitors of HSP90 and kinases are reviewed.
No takes yet. Share an insight, caveat, or question.
Barluenga et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: